A Phase 1/2 interventional study of DIMS and The 0.02% ATP Group in Myopia, sponsored by Ruihua Wei. Recruiting at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Ruihua Wei · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Myopia with a site in China — 81 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.
Among the 220 studies in Myopia with a site in China, this one is the 29th largest by planned enrollment of the 154 interventional ones that give a count, is one of 23 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 34 of the 100 other live ones, and was the 138th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →81 of the 220 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 23 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 410 is above the median of 79 across 926 interventional studies indexed under Myopia.
Median enrollment 149 across the 154 interventional studies, 1,000 across the 66 observational. Of the 76 that completed or were terminated, 5 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 220 have an industry lead sponsor. The 10 most frequent:
Ruihua Wei is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Ruihua Wei has 5 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
33 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT05850936Sun Yat-sen UniversityEffect of IOP Lowering on Progressive HM | 2026-11-20 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 220 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.
In this study, stratified block randomization was employed for random grouping, and the total sample size required as calculated was 410 individuals. Firstly, 410 subjects were assigned ID numbers ranging from 1 to 410. SPSS.26 statistical software was utilized to apply the "random number generator" by setting the "fixed seed number" to "20231121", and subsequently generate random numbers. Once the random numbers were obtained, random sampling and grouping were conducted. This study was a multicenter trial, with block randomization stratified by center. The total sample size of 410 was distributed across 4 cities, and the samples collected in each city were randomly allocated into 5 treatment groups (groups A, B, C, D, and E), with approximately 20 individuals in each group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
wear DIMS ,and use placebo,once nightly, both eye
Device: DIMS
wear SP, and use 0.02%ATP eye drops, once nightly, both eye
Drug: The 0.02% ATP Group
wear SP, and use 0.04%ATP eye drops, once nightly, both eye
Drug: The 0.04% ATP Group
wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
Combination Product: 0.02%ATP+DIMS
wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
Combination Product: 0.04%ATP+DIMS
wear DIMS ,and use placebo,once nightly, both eye
wear SP, and use 0.02%ATP eye drops, once nightly, both eye
wear SP, and use 0.04%ATP eye drops, once nightly, both eye
wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
Best Corrected Visual Acuity
Best Corrected Visual Acuity
Time frame: up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruihua Wei